ArticleFrontiers in medicine2026
Comparative clinical efficacy and immunological modulation of subcutaneous vs. sublingual allergen immunotherapy in children with house dust mite-induced allergic asthma: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The current study compared the clinical efficacy and immunological effects of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) in children with house dust mite (HDM)-induced allergic asthma and explored immune markers associated with treatment response. Methods: The study retrospectively included 125 children with HDM-induced allergic asthma, of which 53 patients received SCIT and 72 patients received SLIT. Clinical outcomes, pulmonary function, and immunological parameters were evaluated at baseline and after 12 months of treatment. Immunological assessments included total IgE, HDM-specific IgE, IgG4, cytokines, peripheral eosinophils, and fractional exhaled nitric oxide (FeNO). Multivariable regression and correlation analyses were performed to identify factors associated with clinical improvement. Results: Both SCIT and SLIT significantly improved asthma control and pulmonary function. ACT scores increased, whereas FeNO levels and eosinophil counts decreased in both groups. IgG4 and IL-10 levels increased significantly, while IL-4 and IL-5 decreased. No significant differences were observed between SCIT and SLIT in the magnitude of these improvements. In exploratory regression analyses, changes in IgG4, IL-10, and IL-4 were associated with improvement in asthma control. Conclusions: In this retrospective cohort, SCIT and SLIT were associated with similar improvements in asthma control, selected pulmonary-function measures, and immune markers over the 12-month observation period. Changes in concomitant asthma medications during follow-up could not be accounted for and may have influenced the observed outcomes. The study did not assess the long-term sustainability of these benefits or post-treatment effects; therefore, longer prospective follow-up is required to evaluate the comparative long-term efficacy of the two treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.